Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board
(NASDAQ: PLRX) Delayed: 1.16 --0 (-0%)
Previous Close $1.16    52 Week High $ 
Open $1.17    52 Week Low $ 
Day High $1.18    P/E N/A 
Day Low $1.14    EPS $ 
Volume 227,794